DOCSLIB.ORG

Appendix C IMIS CIM-2006 V4.2

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Appendix C IMIS CIM-2006 V4.2 Appendix C INDEX TO SUBSTANCES BY IMIS CODE 1. Using the Index 1.1 This index refers Substance Name to the Substance Code (IMIS). The substance name is the primary name listed in either the Michigan rules for Air Contaminants, R 325.51101 - .51108 or Threshold Limit Values and Biological Exposure Indices, ACGIH booklet. 1.2 If the chemical is known, Appendix A, INDEX TO SUBSTANCES BY SYNONYM, will direct you to Chapter II or III. 1.3 If the Chemical Abstract Service Number (CAS No.) is known, Appendix B, INDEX TO SUBSTANCES BY CAS NUMBER, will direct you to Chapter II or III. 2. IMIS Substance Name 0235 ANTU A616 Abietic Acid 0010 Acetaldehyde A625 Acetamide A158 Acetanilide 0020 Acetic Acid 0030 Acetic Anhydride ----------------------------------------------------------------- A505 Acetoacetanilide 0040 Acetone 0060 Acetonitrile A169 Acetophenone A178 Acetylacetone 0065 2-Acetylaminofluorene A206 N-Acetylbenzidine ----------------------------------------------------------------- A179 Acetyl Chloride 0070 Acetylene 0080 Acetylene Tetrabromide A624 Acetyl Methyl Carbinol A629 Acetylsalicylic Acid A257 Acid Black 128 A156 Acid Blue 9 ----------------------------------------------------------------- A256 Acid Orange 74 CIM Ver. 4.2 (10/18/2006) Appendix C Page 1 of 35 A105 Acid Red 114 A177 Acid Yellow 34 A106 Acid Yellow 42 A506 Acridine 0110 Acrolein 0115 Acrylamide ----------------------------------------------------------------- A507 Acrylic acetate 0117 Acrylic acid 0119 Acrylonitrile (CEILING) 0120 Acrylonitrile (PEL) 0121 Acrylonitrile (ACTION LEVEL) A155 Adipic Acid A509 Adiponitrile ----------------------------------------------------------------- 0122 Aflatoxins 0123 Aldicarb 0125 Aldrin T412 Allethrin A515 Allyl Acetate 0130 Allyl Alcohol 0140 Allyl Chloride ----------------------------------------------------------------- A605 Allyl Cyanide A620 Allyl Diglycol Carbonate 0145 Allyl Glycidyl Ether A516 Allyl Methacrylate 0150 Allyl Propyl Disulfide A201 alpha-Alumina (Respirable Fraction) 0160 alpha-Alumina (Total Dust) ----------------------------------------------------------------- A110 Aluminum (as Al), Metal (Respirable Fraction) A100 Aluminum (as Al), Metal (Total Dust) A101 Aluminum (as Al), Pyro Powder A102 Aluminum (as Al), Welding Fumes A103 Aluminum (as Al), Soluble Salts A104 Aluminum (as Al), Alkyls A514 Aluminum Silicate, Fibers ----------------------------------------------------------------- A626 Alupent A623 Amiben 0161 p-Aminoacetanilide A508 p-Aminoazobenzene 0162 4-Aminodiphenyl A615 2-Amino-2-Methylpropanol A606 1-Amino-2-Propanol ----------------------------------------------------------------- A608 3-Amino-1-Propanol CIM Ver. 4.2 (10/18/2006) Appendix C Page 2 of 35 0164 Bis-2-Aminopropyl Ether 0165 2-Aminopyridine A176 Amitrole 0170 Ammonia 0175 Ammonium Chloride (Fume) 0686 Ammonium Dichromate ----------------------------------------------------------------- A613 Ammonium Nitrate A111 Ammonium Sulfamate (Respirable Fraction) 0185 Ammonium Sulfamate (Total Dust) 0190 n-Amyl Acetate 0191 sec-Amyl Acetate A159 n-Amyl Alcohol A612 tert-Amyl Alcohol ----------------------------------------------------------------- A607 Amyl Nitrite 0220 Aniline A517 o-Anisaldehyde 0225 Anisidine (o,p-Isomers) A621 Anisole 0227 Anthracene 0230 Antimony & Compounds (as Sb) ----------------------------------------------------------------- A706 Apron 0240 Argon 0260 Arsenic, Inorganic (PEL) 0261 Arsenic, Inorganic (ACTION LEVEL) A202 Arsenic, Organic Compounds (as As) 0270 Arsine ----------------------------------------------------------------- 9020 Asbestos (all forms) A619 Asbestos (Action Level, State of Oregon Only) 0290 Asphalt Fumes (Petroleum) 0295 Atrazine A609 Auramine A609 Auramine Hydrochloride A618 Azinphos-Ethyl 0300 Azinphos-Methyl ----------------------------------------------------------------- A705 1,1'-Azobisformamide B418 Bacteria B102 Barium (Insoluble Compounds) 0686 Barium Chromate 0310 Barium, Soluble Compounds (as Ba) B104 Barium Sulfate (Respirable Fraction) B101 Barium Sulfate (Total Dust) ----------------------------------------------------------------- 0314 Basic Red 2 CIM Ver. 4.2 (10/18/2006) Appendix C Page 3 of 35 0345 Benefin B405 Benomyl (Respirable Fraction) B407 Benomyl (Total Dust) B105 Benzaldehyde 0350 Benz(a)Anthracene 0320 Benzene ----------------------------------------------------------------- B417 Benzenephosphonic Acid B415 Benzenesulfonic Acid B148 Benzenesulfonyl Chloride 0330 Benzidine B128 Benzidine Based Dyes B717 2,3-Benzofuran B409 Benzoic acid ----------------------------------------------------------------- B505 Benzophenone B727 Benzophenonetetracarboxylic Acid Dianhydride 0726 Benzo (alpha) Pyrene B129 Benzo (e) Pyrene B506 Benzothiazole 0333 2-Benzothiazolethiol B408 Benzotrichloride ----------------------------------------------------------------- B507 Benzoyl Chloride 0335 Benzoyl Peroxide B508 Benzyl Acetate 0337 Benzyl Alcohol B107 Benzyl Bromide 0340 Benzyl Chloride 0360 Beryllium and Beryllium Compounds (as Be) ----------------------------------------------------------------- B509 Betasan B100 Bismuth 0371 Bismuth Telluride, Se Doped B110 Bismuth Telluride, Undoped (Respirable Fraction) 0370 Bismuth Telluride, Undoped (Total Dust) 0372 Bisphenol A B127 Black Powder ----------------------------------------------------------------- 0319 Bladex B135 Boiling Point Range 0374 Borates, Tetra, Sodium Salts, Anhydrous 0375 Borates, Tetra, Sodium Salts, Decahydrate 0376 Borates, Tetra, Sodium Salts, Pentahydrate B141 Boric Acid B142 Boron ----------------------------------------------------------------- CIM Ver. 4.2 (10/18/2006) Appendix C Page 4 of 35 0380 Boron Oxide (Total Dust) 0381 Boron Tribromide 0382 Boron Trifluoride B585 Botran B708 Bromacil B106 Bromelain 0390 Bromine ----------------------------------------------------------------- 0391 Bromine Pentafluoride B137 Bromoacetic Acid B419 Bromobenzene 0400 Bromoform B108 1-Bromonaphthalene B428 Bronkosol 0405 Brucine ----------------------------------------------------------------- 0410 Butadiene 0420 Butane B147 1,3-Butanediol D715 1,4-Butanediol diglycidyl ether 0430 2-Butanone B595 Butene 0435 2-Butoxyethanol ----------------------------------------------------------------- B145 1-Butoxy-2-propanol 0440 n-Butyl Acetate 0441 sec-Butyl Acetate 0442 tert-Butyl Acetate 0450 Butyl Acrylate 0460 n-Butyl Alcohol 0461 sec-Butyl Alcohol 0462 tert-Butyl Alcohol ----------------------------------------------------------------- 0470 Butylamine 0466 N-tert-Butyl-2-Benzothiazolesulfenamide B615 Butyl Benzyl Phthalate 0472 Butyl Cellosolve Acetate 0473 tert-Butyl Chromate (as CrO3), prior to 5/30/2006 0477 n-Butyl Glycidyl Ether B346 tert-Butyl Glycidyl Ether ----------------------------------------------------------------- B609 Butyl Isocyanate 0478 n-Butyl Lactate 0480 Butyl Mercaptan B139 Butyl Methacrylate B146 tert-Butyl Methyl Ether B705 o-sec-Butylphenol CIM Ver. 4.2 (10/18/2006) Appendix C Page 5 of 35 B125 4-tert-Butylphenyl glycidyl ether ----------------------------------------------------------------- B706 Butyl Stearate 2431 Butyltin Trichloride 0485 p-tert-Butyltoluene B707 Butyraldehyde 0487 Butyraldehyde Oxime B709 Butyric Acid ----------------------------------------------------------------- B427 beta-Butyrolactone B715 gamma-Butyrolactone 0490 Cadmium Dust (as Cd) 0491 Cadmium Fume (as Cd) 0500 Calcium Arsenate (as As) 0503 Calcium Bromide ----------------------------------------------------------------- C130 Calcium Carbonate (Respirable Fraction) 0505 Calcium Carbonate (Total Dust) 0686 Calcium Chromate 0510 Calcium Cyanamide 0515 Calcium Hydroxide 0520 Calcium Oxide ----------------------------------------------------------------- C122 Calcium Silicate (Respirable Fraction) C112 Calcium Silicate (Total Dust) C123 Calcium Sulfate (Respirable Fraction) C104 Calcium Sulfate (Total Dust) C118 Camphene 0522 Camphor ----------------------------------------------------------------- 0523 Caprolactam (Dust) 0524 Caprolactam (Vapor) 0528 Captafol 0529 Captan C723 Carbadox 0525 Carbaryl C627 Carbazole ----------------------------------------------------------------- C128 Carbitol Acetate 0526 Carbofuran 0527 Carbon Black 0530 Carbon Dioxide 0540 Carbon Disulfide 0560 Carbon Monoxide 0565 Carbon Tetrabromide ----------------------------------------------------------------- 0570 Carbon Tetrachloride C325 Carbon Tetrafluoride CIM Ver. 4.2 (10/18/2006) Appendix C Page 6 of 35 C105 Carbonyl Fluoride C605 Carbophenothion 0573 Carboxin C606 Carisoprodol 0571 Catechol ----------------------------------------------------------------- C124 Cellulose (Respirable Fraction) 0575 Cellulose (Total Dust) C137 Cellulose Acetate C119 Cerium 0576 Cesium Hydroxide C327 Chloramine-T 0611 Chlordane C139 Chlordimeform ----------------------------------------------------------------- 0612 Chlorinated Camphene 0613 Chlorinated Diphenyl Oxide 0640 Chlorine C110 Chlorine (as Available Chlorine) 0614 Chlorine Dioxide 0615 Chlorine Trifluoride 0617 Chloroacetaldehyde ----------------------------------------------------------------- 0618 alpha-Chloroacetophenone C145 Chloroacetyl Chloride C226 o-Chloroaniline C138 p-Chloroaniline 0620 Chlorobenzene 0623 o-Chlorobenzylidene Malononitrile 0627 Chlorobromomethane 0628 Chlorodifluoromethane ----------------------------------------------------------------- C106 Chlorodiphenyl (21% Cl) C108 Chlorodiphenyl (32% Cl) 0630 Chlorodiphenyl (42% Cl) C225 Chlorodiphenyl (48% Cl) 0631 Chlorodiphenyl
Load more

Recommended publications
  • Pneumocystis Pneumonia and Disseminated
    1614 BRITISH MEDICAL JOURNAL VOLUmE 286 21 MAY 1983 Br Med J (Clin Res Ed): first published as 10.1136/bmj.286.6378.1614-a on 21 May 1983. Downloaded from Pneumocystis pneumonia and discussions, and Dr B Jameson and Dr D G Fleck for their valuable assistance disseminated toxoplasmosis in a with the pneumocystis and toxoplasma serology. Ammann A, Cowan M, Wara D, et al. Possible transfusion-associated male homosexual acquired immune deficiency syndrome (AIDS)-California. Morbidity and Mortality Weekly Report 1982;31 :652-4. 2 Du Bois RM, Branthwaite MA, Mikhail JR, et al. Primary pneumocystis Within the past two years 788 cases of the apparently new and carinii and cytomegalovirus infections. Lancet 1981 ;ii: 1339. potentially lethal syndrome of acquired immune deficiency have been Oswald GA, Theodossi A, Gazzard BG, et al. Attempted immune stimula- reported in the United States.' Only three cases have been reported in tion in the "gay compromise syndrome." Br MedJ' 1982;285:1082. the United Kingdom.2-4 We report a case in a previously healthy 37 4 Maurice PDL, Smith NP, Pinching AJ. Kaposi's sarcoma with benign course in a homosexual. Lancet 1982;i:571. year old male homosexual who was initially diagnosed and treated for Task force on acquired immune deficiency syndrome, Centers for Disease pneumocystis pneumonia and subsequently died of widespread Control. Update on acquired immune deficiency syndrome (AIDS)- toxoplasmosis. United States. Morbidity and Mortality Weekly Report 1982;31:507-14. (Accepted 4 March 1983) Case report The patient presented with an eight week history of malaise, non-produc- Departments of Microbiology and Medicine, St Thomas's Hospital, tive cough, night sweats, diarrhoea, anorexia, and weight loss.
    [Show full text]
  • Aldrich Raman
    Aldrich Raman Library Listing – 14,033 spectra This library represents the most comprehensive collection of FT-Raman spectral references available. It contains many common chemicals found in the Aldrich Handbook of Fine Chemicals. To create the Aldrich Raman Condensed Phase Library, 14,033 compounds found in the Aldrich Collection of FT-IR Spectra Edition II Library were excited with an Nd:YVO4 laser (1064 nm) using laser powers between 400 - 600 mW, measured at the sample. A Thermo FT-Raman spectrometer (with a Ge detector) was used to collect the Raman spectra. The spectra were saved in Raman Shift format. Aldrich Raman Index Compound Name Index Compound Name 4803 ((1R)-(ENDO,ANTI))-(+)-3- 4246 (+)-3-ISOPROPYL-7A- BROMOCAMPHOR-8- SULFONIC METHYLTETRAHYDRO- ACID, AMMONIUM SALT PYRROLO(2,1-B)OXAZOL-5(6H)- 2207 ((1R)-ENDO)-(+)-3- ONE, BROMOCAMPHOR, 98% 12568 (+)-4-CHOLESTEN-3-ONE, 98% 4804 ((1S)-(ENDO,ANTI))-(-)-3- 3774 (+)-5,6-O-CYCLOHEXYLIDENE-L- BROMOCAMPHOR-8- SULFONIC ASCORBIC ACID, 98% ACID, AMMONIUM SALT 11632 (+)-5-BROMO-2'-DEOXYURIDINE, 2208 ((1S)-ENDO)-(-)-3- 97% BROMOCAMPHOR, 98% 11634 (+)-5-FLUORODEOXYURIDINE, 769 ((1S)-ENDO)-(-)-BORNEOL, 99% 98+% 13454 ((2S,3S)-(+)- 11633 (+)-5-IODO-2'-DEOXYURIDINE, 98% BIS(DIPHENYLPHOSPHINO)- 4228 (+)-6-AMINOPENICILLANIC ACID, BUTANE)(N3-ALLYL)PD(II) CL04, 96% 97 8167 (+)-6-METHOXY-ALPHA-METHYL- 10297 ((3- 2- NAPHTHALENEACETIC ACID, DIMETHYLAMINO)PROPYL)TRIPH 98% ENYL- PHOSPHONIUM BROMIDE, 12586 (+)-ANDROSTA-1,4-DIENE-3,17- 99% DIONE, 98% 13458 ((R)-(+)-2,2'- 963 (+)-ARABINOGALACTAN BIS(DIPHENYLPHOSPHINO)-1,1'-
    [Show full text]
  • ATSDR Case Studies in Environmental Medicine Nitrate/Nitrite Toxicity
    ATSDR Case Studies in Environmental Medicine Nitrate/Nitrite Toxicity Agency for Toxic Substances and Disease Registry Case Studies in Environmental Medicine (CSEM) Nitrate/Nitrite Toxicity Course: WB2342 CE Original Date: December 5, 2013 CE Expiration Date: December 5, 2015 Key • Nitrate toxicity is a preventable cause of Concepts methemoglobinemia. • Infants younger than 4 months of age are at particular risk of nitrate toxicity from contaminated well water. • The widespread use of nitrate fertilizers increases the risk of well-water contamination in rural areas. About This This educational case study document is one in a series of and Other self-instructional modules designed to increase the primary Case Studies care provider’s knowledge of hazardous substances in the in environment and to promote the adoption of medical Environmen- practices that aid in the evaluation and care of potentially tal Medicine exposed patients. The complete series of Case Studies in Environmental Medicine is located on the ATSDR Web site at URL: http://www.atsdr.cdc.gov/csem/csem.html In addition, the downloadable PDF version of this educational series and other environmental medicine materials provides content in an electronic, printable format. Acknowledgements We gratefully acknowledge the work of the medical writers, editors, and reviewers in producing this educational resource. Contributors to this version of the Case Study in Environmental Medicine are listed below. Please Note: Each content expert for this case study has indicated that there is no conflict of interest that would bias the case study content. CDC/ATSDR Author(s): Kim Gehle MD, MPH CDC/ATSDR Planners: Charlton Coles, Ph.D.; Kimberly Gehle, MD; Sharon L.
    [Show full text]
  • Nitrocompounds, Aliphatic: Physical & Chemical Properties
    Nitrocompounds, Aliphatic: Physical & Chemical Properties, Encyclopaedia of Occupational Health and Safety, Jeanne Mager Stellman, Editor-in-Chief. International Labor Organization, Geneva. 2011 Chemical Name Colour/Form Boiling Point Melting Molecular Solubility in Relative Density Relative Vapour Inflam. Flash Auto CAS-Number (°C) Point (°C) Weight Water (water=1) Vapour Pressure/ Limits Point (ºC) Ignition Density (Kpa) Point (º C) (air=1) AMYL NITRITE yellowish, transparent 99 117.1 sl sol 0.8828 4.0 110-46-3 liquid 1-CHLORO-1-NITRO- 124.5 109.51 insol 1.2837 ETHANE 598-92-5 2-CHLORO-2-NITRO- liquid 133.6 123.55 0.5 ml sol in 1.197 4.3 8.5 mm Hg 57 ° C oc PROPANE 100 ml @ 20 ° C/20 ° @ 25 ° C 594-71-8 @ 20 ° C C 1-CHLORO-1-NITRO- liquid 143 123.54 0.5ml/100 ml 1.209 0.3 5.8 mm Hg 62 oc PROPANE @ 25 ºC 600-25-9 CHLOROPICRIN slightly oily liquid; 112 -69.2 164.4 sol 1.6558 5.7 5.7 mm Hg 76-06-2 colourless; faint yellow @ 0 º C liquid. 1,1-DICHLORO-1-NI- colourless liquid 124 143.9 0.25 ml/100 m 1.4271 5.0 16.0 mm Hg 76 oc TROETHANE l @ 25 ºC 594-72-9 DIETHYLENE GLYCOL liquid 161 -11.6 sl sol 1.377 DINITRATE @ 25 ºC 693-21-0 ETHYLENE GLYCOL yellowish, oily liquid; 197-200 -22.3 152.06 insol 1.4918 5.24 7 Pa 215 cc 114 DINITRATE colourless 628-96-6 ETHYLENE GLYCOL pale yellow, viscous liquid 197-200 -22.3 152.06 sl sol 1.4978 218 DINITRATE mixed with NITROGLYCERIN (1:1) 53569-64-5 ETHYL NITRATE colourless liquid 87.2 ° C at 762 94.6 ° C 91.07 1.3 g in 100 1.1084 at 20 ° 3.1 lower, 4.0% 10 625-58-1 mm Hg ml C/4 ° C by vol @ 55 ° C ETHYL
    [Show full text]
  • WEST VIRGINIA LEGISLATURE House Bill 2526
    WEST VIRGINIA LEGISLATURE 2017 REGULAR SESSION ENROLLED Committee Substitute for House Bill 2526 BY DELEGATES ELLINGTON, SUMMERS, SOBONYA AND ROHRBACH [Passed April 8, 2017; in effect ninety days from passage.] Enr. CS for HB 2526 1 AN ACT to amend and reenact §60A-2-201, §60A-2-204, §60A-2-206, §60A-2-210 and §60A-2- 2 212 of the Code of West Virginia, 1931, as amended, all relating to classifying additional 3 drugs to Schedules I, II, IV and V of controlled substances; and adding a provision relating 4 to the scheduling of a cannabidiol in a product approved by the Food and Drug 5 Administration. Be it enacted by the Legislature of West Virginia: 1 That §60A-2-201, §60A-2-204, §60A-2-206, §60A-2-210 and §60A-2-212 of the Code of 2 West Virginia, 1931, as amended, be amended and reenacted, all to read as follows: ARTICLE 2. STANDARDS AND SCHEDULES. §60A-2-201. Authority of state Board of Pharmacy; recommendations to Legislature. 1 (a) The state Board of Pharmacy shall administer the provisions of this chapter. It shall 2 also, on the first day of each regular legislative session, recommend to the Legislature which 3 substances should be added to or deleted from the schedules of controlled substances contained 4 in this article or reschedule therein. The state Board of Pharmacy shall also have the authority 5 between regular legislative sessions, on an emergency basis, to add to or delete from the 6 schedules of controlled substances contained in this article or reschedule such substances based 7 upon the recommendations and approval of the federal food, drug and cosmetic agency, and shall 8 report such actions on the first day of the regular legislative session immediately following said 9 actions.
    [Show full text]
  • The History of Glyceryl Trinitrate As a Prescription Drug
    patches for transdermal delivery and in tablet form. It ARTICLE may also be injected. Th e history of glyceryl trinitrate as a prescription drug Anthony Butler Abstract A number of prescribed drugs possessing a nitro group (-NO2) are vasodilators and are used to relieve the symptoms of angina pectoris. Th e most widely pre- scribed drug in this group is glyceryl trinitrate (GTN). It was fi rst synthesized by an Italian chemist, Ascanio Sobrero, in 1847. Its clinical use was pioneered by phy- sicians including William Murrell and Sir Th omas Lauder Brunton, and it is now an established remedy for the condition. Its mode of action in vivo was a com- plete mystery until the discovery in the 1980s of nitric oxide (NO) as the naturally occurring messenger mol- ecule that triggers the process of vasodilation. However, exactly how the nitro group in GTN is converted into NO is still uncertain, although the general belief is that an enzyme is responsible. Introduction Th e nineteenth and twentieth centuries witnessed a Figure 1. Ascanio Sobrero. (Source: University of Torino surge in the number of new compounds made in the Archive) laboratory that were available for testing as possible drugs. Not only were the physical properties (colour, GTN was fi rst synthesised by an Italian, Ascanio So- crystal form, melting point and so on) of new com- brero (1812-1888) around 1847. (Figure 1). He was born pounds recorded, but the discoverer might do a few in the small town of Casale Monferrato in the Pied- simple tests to see whether the compound had any in- mont region of Italy and studied medicine at the near- teresting biological properties.
    [Show full text]
  • NITROGYLCERIN and ETHYLENE GLYCOL DINITRATE Criteria for a Recommended Standard OCCUPATIONAL EXPOSURE to NITROGLYCERIN and ETHYLENE GLYCOL DINITRATE
    CRITERIA FOR A RECOMMENDED STANDARD OCCUPATIONAL EXPOSURE TO NITROGYLCERIN and ETHYLENE GLYCOL DINITRATE criteria for a recommended standard OCCUPATIONAL EXPOSURE TO NITROGLYCERIN and ETHYLENE GLYCOL DINITRATE U.S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE Public Health Service Center for Disease Control National Institute for Occupational Safety and Health June 1978 For »ale by the Superintendent of Documents, U.S. Government Printing Office, Washington, D.C. 20402 DISCLAIMER Mention of company name or products does not constitute endorsement by the National Institute for Occupational Safety and Health. DHEW (NIOSH) Publication No. 78-167 PREFACE The Occupational Safety and Health Act of 1970 emphasizes the need for standards to protect the health and provide for the safety of workers occupationally exposed to an ever-increasing number of potential hazards. The National Institute for Occupational Safety and Health (NIOSH) evaluates all available research data and criteria and recommends standards for occupational exposure. The Secretary of Labor will weigh these recommendations along with other considerations, such as feasibility and means of implementation, in promulgating regulatory standards. NIOSH will periodically review the recommended standards to ensure continuing protection of workers and will make successive reports as new research and epidemiologic studies are completed and as sampling and analytical methods are developed. The contributions to this document on nitroglycerin (NG) and ethylene glycol dinitrate (EGDN) by NIOSH staff, other Federal agencies or departments, the review consultants, the reviewers selected by the American Industrial Hygiene Association, and by Robert B. O ’Connor, M.D., NIOSH consultant in occupational medicine, are gratefully acknowledged. The views and conclusions expressed in this document, together with the recommendations for a standard, are those of NIOSH.
    [Show full text]
  • US5489610.Pdf
    |||||||| US00548961OA United States Patent 19 11 Patent Number: 5,489,610 Fung et al. 45) Date of Patent: 8 Feb. 6, 1996 54 SUSTAINED RELEASE ORGANIC NITRITE 58 Field of Search .................................... 514/506, 509, THERAPY 514/645, 740 75 Inventors: Ho-Leung Fung, Getzville; John A. 56) References Cited Bauer, Williamsville, both of N.Y. U.S. PATENT DOCUMENTS 73 Assignee: Research Foundation of the State 5,278,192 l/1994 Fung et al. .............................. 514f645 University of New York, Albany, N.Y. OTHER PUBLICATIONS * Notice: The portion of the term of this patent Derwent Abstracts 78–35053A, "Medicaments for Treating disclaimed.subsequent to Jan. 11, 2011, has been Cardiardiogenic Shock”, Fribolinis is et al. (1978). Patent Abstracts of Japan, vol. 12, No. 467, Dec. 7, 1988, 21 Appl. No.: 199,280 "Tape Preparation'. 22, PCT Filed: Jun. 30, 1993 Primary Examiner-Frederick Krass Attorney, Agent, or Firm-Kirschstein et al. 86 PCT No.: PCT/US93/06235 (57) ABSTRACT S371 Date: Mar. 1, 1994 A method of treating a patient suffering from a condition S 102(e) Date: Mar. 1, 1994 requiring vasodilator therapy, comprising long term, con 87 PCT Pub. No.: WO94/01103 tinuous adminstration of an organic nitrite to the patient in a dosage form capable of delivering a sufficient therapeutic PCT Pub. Date:Jan. 20, 1994 amount of nitrite to the bloodstream of the patient thereby providing effective vasodilator therapy for at least 24 hours Related U.S. Application Data without the development of tolerance in the patient. The a method of the invention is useful in treating conditions such 63 Continuation-in-part of Ser.
    [Show full text]
  • Effects of Nitric Oxide Synthase Inhibitors on Equine and Bovine Follicular Dynamics and Steroidogenesis
    Louisiana State University LSU Digital Commons LSU Historical Dissertations and Theses Graduate School 2001 Effects of Nitric Oxide Synthase Inhibitors on Equine and Bovine Follicular Dynamics and Steroidogenesis. Carlos Roberto fontes Pinto Louisiana State University and Agricultural & Mechanical College Follow this and additional works at: https://digitalcommons.lsu.edu/gradschool_disstheses Recommended Citation Pinto, Carlos Roberto fontes, "Effects of Nitric Oxide Synthase Inhibitors on Equine and Bovine Follicular Dynamics and Steroidogenesis." (2001). LSU Historical Dissertations and Theses. 430. https://digitalcommons.lsu.edu/gradschool_disstheses/430 This Dissertation is brought to you for free and open access by the Graduate School at LSU Digital Commons. It has been accepted for inclusion in LSU Historical Dissertations and Theses by an authorized administrator of LSU Digital Commons. For more information, please contact [email protected]. INFORMATION TO USERS This manuscript has been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely event that the author did not send UMI a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginning at the upper left-hand comer and continuing from left to right in equal sections with small overlaps.
    [Show full text]
  • ATSDR Case Studies in Environmental Medicine Nitrate/Nitrite Toxicity
    ATSDR Case Studies in Environmental Medicine Nitrate/Nitrite Toxicity Agency for Toxic Substances and Disease Registry Case Studies in Environmental Medicine (CSEM) Nitrate/Nitrite Toxicity Course: WB2342 CE Original Date: December 5, 2013 CE Renewal Date: December 5, 2015 CE Expiration Date: December 5, 2017 Key • Nitrate toxicity is a preventable cause of Concepts methemoglobinemia. • Infants younger than 4 months of age are at particular risk of nitrate toxicity from contaminated well water. • The widespread use of nitrate fertilizers increases the risk of well-water contamination in rural areas. About This and This educational case study document is one in a series of Other Case self-instructional modules designed to increase the Studies in primary care provider’s knowledge of hazardous Environmental substances in the environment and to promote the Medicine adoption of medical practices that aid in the evaluation and care of potentially exposed patients. The complete series of Case Studies in Environmental Medicine is located on the ATSDR Web site at URL: http://www.atsdr.cdc.gov/csem/csem.html In addition, the downloadable PDF version of this educational series and other environmental medicine materials provides content in an electronic, printable format. Acknowledgements We gratefully acknowledge the work of the medical writers, editors, and reviewers in producing this educational resource. Contributors to this version of the Case Study in Environmental Medicine are listed below. Please Note: Each content expert for this case study has indicated that there is no conflict of interest that would bias the case study content. CDC/ATSDR Author(s): Kim Gehle MD, MPH CDC/ATSDR Planners: Charlton Coles, Ph.D.; Kimberly Gehle, MD; Sharon L.
    [Show full text]
  • Continuous-Flow Production of Alkyl Nitrites, Originally Designed by BIOS Chemicals
    FLOW CHEMISTRY Industry Perspective ● Peer reviewed Jean-Christophe M. Continuous-flow production Monbaliu of alkyl nitrites JEAN-CHRISTOPHE M. MONBALIU1*, JEREMY JORDA2, BÉRENGÈRE CHEVALIER2, CHRISTIAN V. STEVENS1, BERNARD MORVAN3 *Corresponding author 1. Ghent University, SynBioC Research Group, Department of Sustainable Organic Chemistry and Technology, Faculty of Bioscience Engineering, Coupure links 653, Gent, B-9000, Belgium 2. CORNING S.A.S, Corning European Technology Center, Avenue de Valvins 7 bis, Avon, F-77210, France 3. BIOS Chemicals, Plateforme technologique DELTA Sud, Verniolle, F- 09340, France the oxidation of olefins (6f, 7c). Recent publications reported ABSTRACT their use for the production of diazonium intermediates in the Alkyl nitrites are important building blocks for the chemical continuous production of synthesis of azo dyes (6c). and pharmaceutical industries. In this article, we report a case study for the continuous-flow production of alkyl nitrites, originally designed by BIOS Chemicals. The PREPARATION OF ALKYL NITRITES intrinsic advantages of a Corning® Advanced-Flow™ reactor system, including high versatility, high mixing, and Numerous methods have been developed at the lab scale heat-exchange efficiency under corrosive conditions, for preparing alkyl nitrites from alcohols: esterification with allowed the development of an economically viable and nitrous acid; transesterification from tert-butyl nitrite (8a) or from user-friendly process in a short period of time, leading to N-nitrosoamines (8b); and nitrosation with various nitrosating a throughput of 10t/year of processed material with high agents such as nitrosyl chloride (8c). Thiols and trimethylsilyl ethers purity (93-98 percent). can also be transformed in the corresponding nitrites (8d). Industrial processes can be divided into two categories: (a) 50 liquid phase processes and (b) vapour phase processes.
    [Show full text]
  • Cocaine/Heroin Induced Rhabdomyolysis and Ventricular Fibrillation B Mccann, R Hunter, J Mccann
    264 CASE REPORTS Emerg Med J: first published as 10.1136/emj.19.3.270 on 1 May 2002. Downloaded from Cocaine/heroin induced rhabdomyolysis and ventricular fibrillation B McCann, R Hunter, J McCann ............................................................................................................................. Emerg Med J 2002;19:264–265 PaO2: 24.3 kPa; base deficit: 18.0 mmol/l; lactate: 8.4 mmol/l. A case of cardiorespiratory arrest in a 28 year old Creatine phosphokinase: 90 500 IU/l (normal range 33–194). man after cocaine and heroin ingestion is described. The Urine: myoglobin: positive; cocaine metabolites: positive; arrest is attributed primarily to hyperkalaemia/ opioids: positive. rhabdomyolysis—a recognised consequence of each of Consequent upon his rhabdomyolysis he developed acute these drugs. The administration of naloxone may have renal failure requiring haemodialysis, disseminated intravas- been contributory. He developed acute renal failure, cular coagulopathy and right lower limb compartment disseminated intravascular coagulopathy with consequent syndrome requiring fasciotomy. Echocardiogram showed a lower limb compartment syndrome requiring fasciotomy. left ventricular ejection fraction of 53%. Respiratory function Ventricular fibrillation was identified at thoracotomy. remained stable. At day 10 (after tracheostomy) he had spon- taneous eye opening, flexed to pain and had no response to verbal commands. Brain stem reflexes were intact. Computed tomographic scan of his brain was normal. 28 year old man was brought to the emergency depart- The patient died two months later. Cause of death was ment after intravenous ingestion of cocaine and heroin. bronchopneumonia complicating multiorgan failure. AHe was noted to be pale, cyanosed, bradypnoeic (6/min), and hypotensive (70/40). DISCUSSION Initial treatment consisted of oxygen via a facemask, and 800 Rhabdomyolysis is a well documented complication of cocaine µg of naloxone intravenously.
    [Show full text]